

Antenatal corticosteroids and brain development : the use of S100B as an early predictor of brain impairment

Citation for published version (APA):

Bruschettini, M. (2007). *Antenatal corticosteroids and brain development : the use of S100B as an early predictor of brain impairment*. [Doctoral Thesis, Maastricht University]. Universiteit Maastricht. <https://doi.org/10.26481/dis.20071114mb>

Document status and date:

Published: 01/01/2007

DOI:

[10.26481/dis.20071114mb](https://doi.org/10.26481/dis.20071114mb)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Summary

Infant respiratory distress syndrome (RDS) is a life-threatening disorder caused by developmental insufficiency of surfactant production and structural immaturity in the lungs of preterm infants. The use of antenatal betamethasone (AB) has resulted in a significant decrease in neonatal mortality and morbidity. However, this treatment strategy may also cause a wide range of side effects in humans, like impairments in somatic growth, brain development and hypothalamic-pituitary-adrenal function. In the present work, the short- and long-term consequences of AB on offspring development were analyzed in human infants and in the rat. Within the rat model, a lower dose regimen of AB was used in order to assess whether lowering the dose might induce milder side effects. The main findings of this thesis are:

In the clinic, AB induced a reduction of neurotrophic S100B protein in the urine of the human newborns (*Chapter 2*). Of note, in this clinical study, only the standard dose regimen (12 mg twice 24 hours apart) was used.

In the rat, AB resulted in a significant dose-dependent growth restriction in both genders. Moreover, AB reduced hippocampal S100B concentrations and cell proliferation within the brain of neonatal male offspring (*Chapters 3 and 4*). S100B levels were also reduced in the male blood by the the lower dose (6 mg) of AB.

In adult offspring AB did not affect cognition- and anxiety-related behavior and synaptophysin immunoreactivity (IR) within the hippocampus. However, MAP2-IR was reduced in male adult rats treated with AB (*Chapter 5*).

Overall, males were more affected as compared to females, the latter of which showed no impairment in neonatal hippocampal S100B levels, brain cell proliferation and MAP2-IR within the adult hippocampus.

Halving the dose of AB resulted in less growth restriction. Further, no impairment of neonatal hippocampal S100B concentration and cell proliferation within the brain was observed by using the lower dose.

In conclusion, the present work confirms that a single course of AB might induce permanent consequences on offspring development. A lower dose of AB (equivalent to 6 mg twice 24 hours apart) induced milder effects, supporting the idea that reducing the dose might be less harmful. First however, clinical trials need to show whether different dose regimens could promote proper lung maturation without impairing brain development.